Dr. Kit L. Cheng, MD

Dr. Cheng practices at Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York.

Dr. Cheng's NPI, 1316106834, was assigned on June 9, 2008. Dr. Cheng graduated from University at Buffalo School of Medicine in 2003. Dr. Cheng holds New York license 239216.

Dr. Cheng's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center, at 450 Lakeville Rd, Lake Success, NY 11042. The practice phone is (516) 734-8281.

Dr. Cheng's primary practice is Schlanger, Gottlieb Partners Council Breast Imaging Center in Lake Success, New York. Dr. Cheng is also affiliated with Long Island Jewish Medical Center. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Cheng to 2 more hospitals, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account. Dr. Cheng's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cheng practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cheng's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cheng is licensed in New York.

CMS data shows 1,027 Medicare services from Dr. Cheng across 8 procedure codes in 2024, for 362 Medicare patients. Medicare paid $80,650 for them.

CMS counts 362 Medicare patients who saw Dr. Cheng in 2024. The largest group is 65 to 74, with 167 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cheng's median patient age at 69, with 93% women.

In 2024, Dr. Cheng wrote 994 Medicare Part D claims for 276 patients. 88% of them were for generic drugs. CMS names the drug for 765 of them, across 14 drugs with 11 or more claims each, at $976,463 in total drug cost. In 2023, CMS named 663 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Cheng for performance year 2024, reported as part of a group. Dr. Cheng accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cheng as offering telehealth.

Dmand AI links 12 papers to Dr. Cheng, published from 2017 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and China. Dr. Cheng has published most often in Emerg Infect Dis. Dr. Cheng's most frequent co-authors are Vandana Gupta Abramson, MD, Blair Ardman, MD and Ron Bose, MD.

Dmand AI links Dr. Cheng to 4 clinical trials, 3 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Brain Neoplasms, Breast Neoplasms and Breast Diseases. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 8 general payments to Dr. Cheng from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. GlaxoSmithKline, LLC. paid the most, $1,625.

Dr. Cheng graduated from University at Buffalo School of Medicine in 2003.